Orion Corp
KRX:271560
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
83 900
117 800
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Orion Corp
Orion Corp
Income from Continuing Operations
Orion Corp
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Orion Corp
KRX:271560
|
Income from Continuing Operations
₩392.7B
|
CAGR 3-Years
17%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
CJ CheilJedang Corp
KRX:097950
|
Income from Continuing Operations
₩666.6B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
70%
|
CAGR 10-Years
29%
|
|
|
Ottogi Corp
KRX:007310
|
Income from Continuing Operations
₩164.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
10%
|
CAGR 10-Years
5%
|
|
|
S
|
Samyang Foods Co Ltd
KRX:003230
|
Income from Continuing Operations
₩226.9B
|
CAGR 3-Years
74%
|
CAGR 5-Years
38%
|
CAGR 10-Years
46%
|
|
|
Dongwon Industries Co Ltd
KRX:006040
|
Income from Continuing Operations
₩96B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
2%
|
CAGR 10-Years
7%
|
|
|
Nongshim Co Ltd
KRX:004370
|
Income from Continuing Operations
₩155.2B
|
CAGR 3-Years
13%
|
CAGR 5-Years
16%
|
CAGR 10-Years
6%
|
|
Orion Corp
Glance View
Perched within the competitive landscape of pharmaceuticals, Orion Corporation has steadily carved its niche since its inception in Finland in 1917. Starting as a small-scale factory operation, Orion has evolved into a pivotal player in the healthcare sector, blending traditional expertise with cutting-edge innovations. The company's core operations pivot around the development, manufacturing, and marketing of human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients (APIs). This dual focus allows Orion not only to reach a diverse market but also ensures a consistent revenue stream, supplemented by its strategic interest in self-care products. The company thrives on its robust research and development arm, constantly seeking innovations in therapeutic areas like central nervous system disorders, oncology, and respiratory diseases. Orion's financial engine hums efficiently through its vertically integrated business model. By managing most of the value chain internally—from drug discovery to production and distribution—Orion secures cost advantages and quality control, translating into a competitive edge in global markets. While Europe remains Orion's stronghold, it strategically seeks growth in regional markets, leveraging partnerships and alliances with international pharmaceutical giants to expand its footprint. This strategy not only augments its own pipeline with licensed products but also fortifies its market position, making it a sustainable player in an industry driven by constant change and regulated rigorously. The corporation's revenue streams thus embody a careful balance of organic product development and strategic collaborations, evidencing a business acumen grounded in long-term vision.
See Also
What is Orion Corp's Income from Continuing Operations?
Income from Continuing Operations
392.7B
KRW
Based on the financial report for Sep 30, 2024, Orion Corp's Income from Continuing Operations amounts to 392.7B KRW.
What is Orion Corp's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
18%
Over the last year, the Income from Continuing Operations growth was -10%. The average annual Income from Continuing Operations growth rates for Orion Corp have been 17% over the past three years , 18% over the past five years .
You don't have any saved screeners yet